Skip to main content

Advertisement

SpringerLink
Log in

When to start antiretroviral therapy and what to start with—a European perspective

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Although antiretroviral combination therapy has greatly improved the life expectancy of HIV-infected individuals, its use is hampered by considerable toxicity, the need for life-long near-perfect adherence to strict dosing regimens in order to avoid the emergence of drug resistance, and high cost. In this paper we review current understanding of when to best initiate antiretroviral therapy and what regimen to start with. The limitations of antiretroviral combination therapy are increasingly clear, and this has led to the current tendency to delay the initiation of therapy until CD4 cell counts have consistently dropped toward the 200 cells/mm3 mark, or until plasma HIV-1 RNA has increased to above 100,000 copies/mL. The need for optimal adherence also implies a "readiness" on the part of the patient to start treatment. Once the decision to commence therapy has been reached, what particular combinations of drugs to start with increasingly demands an individualized approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996, 276:146–154.

    Article  PubMed  CAS  Google Scholar 

  2. Larder BA, Kellam P, Kemp SD: Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 1993, 365:451–453.

    Article  PubMed  CAS  Google Scholar 

  3. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117–122.

    Article  PubMed  CAS  Google Scholar 

  4. Preston BD, Poiesz BJ, Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science 1988, 242:1168–1171.

    Article  PubMed  CAS  Google Scholar 

  5. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734–739.

    Article  PubMed  CAS  Google Scholar 

  6. Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999, 341:1865–1873.

    Article  PubMed  CAS  Google Scholar 

  7. Staszewski S, Keiser P, Montaner J, et al.: Abacavir-lamivudinezidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001, 285:1155–1163.

    Article  PubMed  CAS  Google Scholar 

  8. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962–1969.

    Article  PubMed  CAS  Google Scholar 

  9. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee. Lancet 1997,349:1086–1092.

  10. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78–86.

    Article  PubMed  CAS  Google Scholar 

  11. Montaner JS, Hogg R, Raboud J, Harrigan R, O’Shaughnessy M: Antiretroviral treatment in 1998. Lancet 1998, 352:1919–1922.

    Article  PubMed  CAS  Google Scholar 

  12. Moyle GJ, Gazzard BG, Cooper DA, Gatell J: Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs 1998, 55:383–404.

    Article  PubMed  CAS  Google Scholar 

  13. Carpenter CC, Cooper DA, Fischl MA, et al.: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381–390.

    Article  PubMed  CAS  Google Scholar 

  14. Ledergerber B, Egger M, Erard V, et al.: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999, 282:2220–2226.

    Article  PubMed  CAS  Google Scholar 

  15. Hogg RS, Yip B, Kully C, et al.: Improved survival among HIVinfected patients after initiation of triple-drug antiretroviral regimens. Can Med Assoc J 1999, 160:659–665.

    CAS  Google Scholar 

  16. Wit FW, van Leeuwen R, Weverling GJ, et al.: Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999, 179:790–798.

    Article  PubMed  CAS  Google Scholar 

  17. Weverling GJ, Mocroft A, Ledergerber B, et al.: Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999, 353:1293–1298.

    Article  PubMed  CAS  Google Scholar 

  18. Ledergerber B, Mocroft A, Reiss P, et al.: Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001, 344:168–174.

    Article  PubMed  CAS  Google Scholar 

  19. Kirk O, Reiss P, Uberti-Foppa C, et al.: Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002, 137:239–250.

    PubMed  Google Scholar 

  20. Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123–126.

    Article  PubMed  CAS  Google Scholar 

  21. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995, 333:450–451.

    Article  PubMed  CAS  Google Scholar 

  22. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295–1300.

    Article  PubMed  CAS  Google Scholar 

  23. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997, 94:13193–13197.

    Article  PubMed  CAS  Google Scholar 

  24. Zhang H, Dornadula G, Beumont M, et al.: Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998, 339:1803–1809.

    Article  PubMed  CAS  Google Scholar 

  25. Schuetz JD, Connelly MC, Sun D, et al.: MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999, 5:1048–1051.

    Article  PubMed  CAS  Google Scholar 

  26. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A 1999, 96:10958–10961.

    Article  PubMed  CAS  Google Scholar 

  27. Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21–30.

    PubMed  CAS  Google Scholar 

  28. Fatkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113–116.

    Article  PubMed  CAS  Google Scholar 

  29. Bonfanti P, Capetti A, Di Mattei P, et al.: Virological treatment failure of highly active antiretroviral therapy in an unselected cohort of HIV-infected patients. AIDS 1998, 12:1111.

    PubMed  CAS  Google Scholar 

  30. Kaufmann D, Pantaleo G, Sudre P, Telenti A: CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998, 351:723–724.

    Article  PubMed  CAS  Google Scholar 

  31. Belec L, Piketty C, Si-Mohamed A, et al.: High levels of drugresistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis 2000, 181:1808–1812.

    Article  CAS  Google Scholar 

  32. Deeks SG, Barbour JD, Martin JN, et al.: Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000, 181:946–953.

    Article  PubMed  CAS  Google Scholar 

  33. Borleffs JC, Danner SA, Lange JM, van Everdingen JJ: CBO guidelines antiretroviral therapy in the Netherlands. Ned Tijdschr Geneeskd 2001, 145:1585–1589.

    PubMed  CAS  Google Scholar 

  34. Sterling TR, Chaisson RE, Moore RD: HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001, 15:2251–2257.

    Article  PubMed  CAS  Google Scholar 

  35. Boyle BA: Issues in antiretroviral therapy: when to start? AIDS Read 2001, 11:66–70.

    PubMed  CAS  Google Scholar 

  36. Yeni PG, Hammer SM, Carpenter CC, et al.: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222–235. These authorative guidelines have recently been updated and acknowledge that the limited potency and considerable toxicity of current therapies have led to a more conservative approach with regard to initiating antiretroviral therapy.

    Article  PubMed  CAS  Google Scholar 

  37. Guidelines for using antiretroviral agents among HIVinfected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002, 51:1–55. These guidelines place much emphasis on the importance of the "readiness" of the patient to initiate antiretroviral therapy and to tailoring the initial regimen to the needs of the individual patient.

  38. Hogg RS, Yip B, Chan KJ, et al.: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568–2577. This large cohort study demonstrates low rates of disease progression and death among HIV-infected individuals commencing antiretroviral therapy with CD4 cell count over 200 cells/mm3.

    Article  PubMed  CAS  Google Scholar 

  39. Phillips AN, Staszewski S, Weber R, et al.: HIV viral load response to antiretroviral therapy according to the baseline cd4 cell count and viral load. JAMA 2001, 286:2560–2567. In this large collaborative cohort study, there was no strong evidence that lower CD4 counts and higher levels of plasma viremia at the start of antiretroviral therapy were associated with poorer virologic outcome.

    Article  PubMed  CAS  Google Scholar 

  40. Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119–129. The Antiretroviral Therapy Cohort Collaboration, which included data from 13 cohort studies, reported that the CD4 count at the start of antiretroviral therapy was the dominant prognostic factor for the occurrence of disease progression or death. There were only minor differences in the risk of disease progression between patients with baseline CD4 counts over 350 and patients with CD4 count between 200 and 350.

    Article  PubMed  Google Scholar 

  41. Grabar S, Le Moing V, Goujard C, et al.: Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000, 133:401–410.

    PubMed  CAS  Google Scholar 

  42. Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447–1450.

    Article  PubMed  CAS  Google Scholar 

  43. Rosenberg ES, Altfeld M, Poon SH, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523–526.

    Article  PubMed  CAS  Google Scholar 

  44. Brinkman K, ter Hofstede HJ, Burger DM, et al.: Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998, 12:1735–1744.

    Article  PubMed  CAS  Google Scholar 

  45. Brinkman K, Smeitink JA, Romijn JA, Reiss P: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999, 354:1112–1115.

    Article  PubMed  CAS  Google Scholar 

  46. Clay PG, Rathbun RC, Slater LN: Management protocol for abacavir-related hypersensitivity reaction. Ann Pharmacother 2000, 34:247–249.

    Article  PubMed  CAS  Google Scholar 

  47. Wit FW, Wood R, Horban A, et al.: Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 2001, 15:2423–2429.

    Article  PubMed  CAS  Google Scholar 

  48. Wit FW, Weverling GJ, Weel J, et al.: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002, 186:23–31.

    Article  PubMed  CAS  Google Scholar 

  49. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.

    Article  PubMed  CAS  Google Scholar 

  50. Carr A, Samaras K, Thorisdottir A, et al.: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093–2099.

    Article  PubMed  CAS  Google Scholar 

  51. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257–275.

    PubMed  Google Scholar 

  52. Hurst M, Faulds D: Lopinavir. Drugs 2000, 60:1371–1379.

    Article  PubMed  CAS  Google Scholar 

  53. D’Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996, 124:1019–1030.

    PubMed  CAS  Google Scholar 

  54. Montaner JS, Reiss P, Cooper D, et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998, 279:930–937.

    Article  PubMed  CAS  Google Scholar 

  55. van Leth F: Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine [abstract 176]. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston. February 10–14, 2003.

  56. Staszewski S, Katlama C, Harrer T, et al.: A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998, 12:F197–202.

    Article  PubMed  CAS  Google Scholar 

  57. van Leeuwen R, Katlama C, Murphy R, et al.: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003, 17:987–999.

    Article  PubMed  CAS  Google Scholar 

  58. Moyle G: Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 2001, 11:87–98.

    PubMed  CAS  Google Scholar 

  59. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385–394.

    Article  PubMed  CAS  Google Scholar 

  60. Prins JM, Jurriaans S, van Praag RM, et al.: Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999, 13:2405–2410.

    Article  PubMed  CAS  Google Scholar 

  61. Weverling GJ, Lange JM, Jurriaans S, et al.: Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998, 12:F117–122.

    Article  PubMed  CAS  Google Scholar 

  62. van Praag RM, Wit FW, Jurriaans S, de Wolf F, et al.: Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS 2002, 16:719–725.

    Article  PubMed  Google Scholar 

  63. Dybul M, Chun TW, Yoder C, et al.: Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 2001, 98:15161–15166.

    Article  PubMed  CAS  Google Scholar 

  64. Neumann AU, Tubiana R, Calvez V, et al.: HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999, 13:677–683.

    Article  PubMed  CAS  Google Scholar 

  65. Reijers MH, Weverling GJ, Jurriaans S, et al.: Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998, 352:185–190.

    Article  PubMed  CAS  Google Scholar 

  66. Hall DB, Montaner JG, Reiss P, et al.: Induction-maintenance antiretroviral therapy: proof of concept. AIDS 1998, 12:F41–44.

    Article  PubMed  CAS  Google Scholar 

  67. Martinez E, Conget I, Lozano L, et al.: Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999, 13:805–810.

    Article  PubMed  CAS  Google Scholar 

  68. Barreiro P, Soriano V, Blanco F, et al.: Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000, 14:807–812.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Antiviral Therapy Evaluation Center, Academic Medical Center, Room T0-120, Meibergdreef 9, 1105, AZ Amsterdam, The Netherlands

    Ferdinand W. N. M. Wit MD, PhD

Authors
  1. Ferdinand W. N. M. Wit MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Reiss MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wit, F.W.N.M., Reiss, P. When to start antiretroviral therapy and what to start with—a European perspective. Curr Infect Dis Rep 5, 349–357 (2003). https://doi.org/10.1007/s11908-003-0013-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-003-0013-y

Keywords

Search

Navigation